Intersect ENT Gets a Hold Rating from Northland Securities


In a report released today, Suraj Kalia from Northland Securities maintained a Hold rating on Intersect ENT (NASDAQ: XENT), with a price target of $32. The company’s shares opened today at $41.45, close to its 52-week high of $42.25.

According to TipRanks.com, Kalia is a 4-star analyst with an average return of 7.9% and a 59.8% success rate. Kalia covers the Healthcare sector, focusing on stocks such as EyePoint Pharmaceuticals Inc, Tactile Systems Technology, and Obalon Therapeutics Inc.

Currently, the analyst consensus on Intersect ENT is Moderate Buy and the average price target is $40.75, representing a -1.7% downside.

In a report issued on May 1, BTIG also maintained a Hold rating on the stock.

See today’s analyst top recommended stocks >>

Based on Intersect ENT’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $6.14 million. In comparison, last year the company had a GAAP net loss of $6.68 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Intersect ENT, Inc. is a medical technology company, which is dedicated in the treatment of ear, nose, and throat conditions through evidence-based innovation, providing physicians with solutions to improve quality of life for patients. The company was founded by Donald J. Eaton in October 2003 and is headquartered in Menlo Park, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts